Ever-Growing USA on MSN2d
Retratutide: Eli Lilly’s Groundbreaking Drug for Obesity & Diabetes
In the ever-evolving landscape of healthcare, groundbreaking innovations are not merely celebrated for their scientific ...
Can BIIB's New Drugs Revive Growth as Multiple Sclerosis Sales Fall?
Biogen believes that some of its new drugs, Leqembi, Skyclarys and Zurzuvae, have the potential to revive long-term growth. Can Biogen achieve this goal?
STAT3d
Altimmune to study obesity drug in alcohol use disorder, following Eli Lilly
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
MedPage Today6d
Brain Edema, Imaging Abnormalities Reported for Alzheimer's Drug
Treatment with donanemab (Kisunla) raised the risk of amyloid-related imaging abnormalities (ARIA) in people with early ...
‘Miracle’ Alzheimer’s drug ‘triggers deadly brain bleeds in up to a third’, new study finds
AN ALZHEIMER’S drug hailed as a ‘miracle’ medicine for dementia may cause life-threatening brain bleeds in a third of ...
Zacks Investment Research on MSN6d
Eli Lilly Rises 7.5% YTD: Time to Buy, Sell or Hold the Stock?
Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from ...